{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,3]],"date-time":"2026-06-03T17:27:25Z","timestamp":1780507645742,"version":"3.54.1"},"reference-count":44,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,9,10]],"date-time":"2020-09-10T00:00:00Z","timestamp":1599696000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2020,9,10]],"date-time":"2020-09-10T00:00:00Z","timestamp":1599696000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Medical Scientific Fund of the Mayor of the City of Vienna"},{"name":"\u2018Initiative Krebsforschung\u2019 of the Medical University of Vienna"},{"name":"Herzfelder Familienstiftung, Vienna"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Fatty-acid(FA)-synthase(FASN) is a druggable lipogenic oncoprotein whose blockade causes metabolic disruption. Whether drug-induced metabolic perturbation is essential for anticancer drug-action, or is just a secondary\u2014maybe even a defence response\u2014is still unclear. To address this, SKOV3 and OVCAR3 ovarian cancer(OC) cell lines with clear cell and serous histology, two main OC subtypes, were exposed to FASN-inhibitor G28UCM. Growth-inhibition was compared with treatment-induced cell-metabolomes, lipidomes, proteomes and kinomes. SKOV3 and OVCAR3 were equally sensitive to low-dose G28UCM, but SKOV3 was more resistant than OVCAR3 to higher concentrations. Metabolite levels generally decreased upon treatment, but individual acylcarnitines, glycerophospholipids, sphingolipids, amino-acids, biogenic amines, and monosaccharides reacted differently. Drug-induced effects on central-carbon-metabolism and oxidative-phosphorylation (OXPHOS) were essentially different in the two cell lines, since drug-na\u00efve SKOV3 are known to prefer glycolysis, while OVCAR3 favour OXPHOS. Moreover, drug-dependent increase of desaturases and polyunsaturated-fatty-acids (PUFAs) were more pronounced in SKOV3 and appear to correlate with G28UCM-tolerance. In contrast, expression and phosphorylation of proteins that control apoptosis, FA synthesis and membrane-related processes (beta-oxidation, membrane-maintenance, transport, translation, signalling and stress-response) were concordantly affected. Overall, membrane-disruption and second-messenger-silencing were crucial for anticancer drug-action, while metabolic-rewiring was only secondary and may support high-dose-FASN-inhibitor-tolerance. These findings may guide future anti-metabolic cancer intervention.<\/jats:p>","DOI":"10.1038\/s41598-020-71491-z","type":"journal-article","created":{"date-parts":[[2020,9,10]],"date-time":"2020-09-10T10:03:14Z","timestamp":1599732194000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":16,"title":["Membrane disruption, but not metabolic rewiring, is the key mechanism of anticancer-action of FASN-inhibitors: a multi-omics analysis in ovarian cancer"],"prefix":"10.1038","volume":"10","author":[{"given":"Thomas W.","family":"Grunt","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Astrid","family":"Slany","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mariya","family":"Semkova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ram\u00f3n","family":"Colomer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mar\u00eda Luz","family":"L\u00f3pez-Rodr\u00edguez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Wuczkowski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Renate","family":"Wagner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher","family":"Gerner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gerald","family":"St\u00fcbiger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,9,10]]},"reference":[{"key":"71491_CR1","doi-asserted-by":"publisher","first-page":"551","DOI":"10.2217\/fon.10.11","volume":"6","author":"R Flavin","year":"2010","unstructured":"Flavin, R., Peluso, S., Nguyen, P. L. & Loda, M. Fatty acid synthase as a potential therapeutic target in cancer. Future Oncol. 6, 551\u2013562. https:\/\/doi.org\/10.2217\/fon.10.11 (2010).","journal-title":"Future Oncol."},{"key":"71491_CR2","doi-asserted-by":"publisher","first-page":"829","DOI":"10.1038\/nrd4145","volume":"12","author":"L Galluzzi","year":"2013","unstructured":"Galluzzi, L., Kepp, O., Vander Heiden, M. G. & Kroemer, G. Metabolic targets for cancer therapy. Nat. Rev. Drug. Discov. 12, 829\u2013846. https:\/\/doi.org\/10.1038\/nrd4145 (2013).","journal-title":"Nat. Rev. Drug. Discov."},{"key":"71491_CR3","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1016\/j.tem.2017.11.003","volume":"29","author":"TW Grunt","year":"2018","unstructured":"Grunt, T. W. Interacting cancer machineries: cell signalling, lipid metabolism, and epigenetics. Trends Endocrinol. Metab. 29, 86\u201398. https:\/\/doi.org\/10.1016\/j.tem.2017.11.003 (2018).","journal-title":"Trends Endocrinol. Metab."},{"key":"71491_CR4","doi-asserted-by":"publisher","first-page":"631","DOI":"10.1073\/pnas.1808834116","volume":"116","author":"G Zadra","year":"2019","unstructured":"Zadra, G. et al. Inhibition of de novo lipogenesis targets androgen receptor signalling in castration-resistant prostate cancer. Proc. Natl. Acad. Sci. USA 116, 631\u2013640. https:\/\/doi.org\/10.1073\/pnas.1808834116 (2019).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"71491_CR5","doi-asserted-by":"publisher","first-page":"1187","DOI":"10.1080\/17460441.2016.1245286","volume":"11","author":"TS Angeles","year":"2016","unstructured":"Angeles, T. S. & Hudkins, R. L. Recent advances in targeting the fatty acid biosynthetic pathway using fatty acid synthase inhibitors. Expert. Opin. Drug. Discov. 11, 1187\u20131199 (2016).","journal-title":"Expert. Opin. Drug. Discov."},{"key":"71491_CR6","doi-asserted-by":"publisher","first-page":"e0131241","DOI":"10.1371\/journal.pone.0131241","volume":"10","author":"A Blancafort","year":"2015","unstructured":"Blancafort, A. et al. Dual fatty acid synthase and HER2 signalling blockade shows marked antitumor activity against breast cancer models resistant to anti-HER2 drugs. PLoS ONE 10, e0131241. https:\/\/doi.org\/10.1371\/journal.pone.0131241 (2015).","journal-title":"PLoS ONE"},{"key":"71491_CR7","doi-asserted-by":"publisher","first-page":"E4330","DOI":"10.3390\/ijms20184330","volume":"20","author":"S Nagasawa","year":"2019","unstructured":"Nagasawa, S. et al. Systematic identification of characteristic genes of ovarian clear cell carcinoma compared with high-grade serous carcinoma based on RNA-sequencing. Int. J. Mol. Sci. 20, E4330. https:\/\/doi.org\/10.3390\/ijms20184330 (2019).","journal-title":"Int. J. Mol. Sci."},{"key":"71491_CR8","doi-asserted-by":"publisher","first-page":"2078","DOI":"10.1002\/ijc.29261","volume":"136","author":"D Veigel","year":"2015","unstructured":"Veigel, D. et al. Fatty acid synthase is a metabolic marker of cell proliferation rather than malignancy in ovarian cancer and its precursor cells. Int. J. Cancer 136, 2078\u20132090. https:\/\/doi.org\/10.1002\/ijc.29261 (2015).","journal-title":"Int. J. Cancer"},{"key":"71491_CR9","doi-asserted-by":"publisher","first-page":"11600","DOI":"10.18632\/oncotarget.14591","volume":"8","author":"R Wagner","year":"2017","unstructured":"Wagner, R. et al. Multi-level suppression of receptor-PI3K-mTORC1 by fatty acid synthase inhibitors is crucial for their efficacy against ovarian cancer cells. Oncotarget 8, 11600\u201311613. https:\/\/doi.org\/10.18632\/oncotarget.14591 (2017).","journal-title":"Oncotarget"},{"key":"71491_CR10","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1080\/07388550600697479","volume":"26","author":"D Warude","year":"2006","unstructured":"Warude, D., Joshi, K. & Harsulkar, A. Polyunsaturated fatty acids: biotechnology. Crit. Rev. Biotechnol. 26, 83\u201393 (2006).","journal-title":"Crit. Rev. Biotechnol."},{"key":"71491_CR11","doi-asserted-by":"publisher","first-page":"808","DOI":"10.1016\/j.ebiom.2015.06.020","volume":"2","author":"R Ventura","year":"2015","unstructured":"Ventura, R. et al. Inhibition of de novo palmitate synthesis by fatty acid synthase induces apoptosis in tumor cells by remodeling cell membranes, inhibiting signalling pathways, and reprogramming gene expression. EBioMedicine 2, 808\u2013824. https:\/\/doi.org\/10.1016\/j.ebiom.2015.06.020 (2015).","journal-title":"EBioMedicine"},{"key":"71491_CR12","doi-asserted-by":"publisher","first-page":"454","DOI":"10.1016\/j.bbrc.2009.05.085","volume":"385","author":"TW Grunt","year":"2009","unstructured":"Grunt, T. W. et al. Interaction between fatty acid synthase- and ErbB-systems in ovarian cancer cells. Biochem. Biophys. Res. Commun. 385, 454\u2013459. https:\/\/doi.org\/10.1016\/j.bbrc.2009.05.085 (2009).","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"71491_CR13","doi-asserted-by":"publisher","first-page":"1767","DOI":"10.1158\/1541-7786.MCR-10-0467","volume":"9","author":"K Tomek","year":"2011","unstructured":"Tomek, K. et al. Blockade of fatty acid synthase induces ubiquitination and degradation of phosphoinositide-3-kinase signalling proteins in ovarian cancer. Mol. Cancer Res. 9, 1767\u20131779. https:\/\/doi.org\/10.1158\/1541-7786.MCR-10-0467 (2011).","journal-title":"Mol. Cancer Res."},{"key":"71491_CR14","doi-asserted-by":"publisher","first-page":"2767","DOI":"10.1111\/febs.13681","volume":"283","author":"B Peck","year":"2016","unstructured":"Peck, B. & Schulze, A. Lipid desaturation: the next step in targeting lipogenesis in cancer?. FEBS J. 283, 2767\u20132778. https:\/\/doi.org\/10.1111\/febs.13681 (2016).","journal-title":"FEBS J."},{"key":"71491_CR15","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1038\/nrm.2017.61","volume":"18","author":"E Zlotorynski","year":"2017","unstructured":"Zlotorynski, E. Gene expression: ACSS2 boosts local histone acetylation. Nat. Rev. Mol. Cell Biol. 18, 405. https:\/\/doi.org\/10.1038\/nrm.2017.61 (2017).","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"71491_CR16","doi-asserted-by":"publisher","first-page":"26430","DOI":"10.1074\/jbc.271.42.26430","volume":"271","author":"JW Hawes","year":"1996","unstructured":"Hawes, J. W. et al. Primary structure and tissue-specific expression of human beta-hydroxyisobutyryl-coenzyme A hydrolase. J. Biol. Chem. 271, 26430\u201326434 (1996).","journal-title":"J. Biol. Chem."},{"key":"71491_CR17","doi-asserted-by":"publisher","first-page":"370","DOI":"10.1016\/j.bbcan.2012.06.004","volume":"1826","author":"JQ Chen","year":"2012","unstructured":"Chen, J. Q. & Russo, J. Dysregulation of glucose transport, glycolysis, TCA cycle and glutaminolysis by oncogenes and tumour suppressors in cancer cells. Biochim. Biophys. Acta 1826, 370\u2013384. https:\/\/doi.org\/10.1016\/j.bbcan.2012.06.004 (2012).","journal-title":"Biochim. Biophys. Acta"},{"key":"71491_CR18","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1016\/j.cmet.2010.05.001","volume":"11","author":"P Kapahi","year":"2010","unstructured":"Kapahi, P. et al. With TOR, less is more: a key role for the conserved nutrient-sensing TOR pathway in aging. Cell Metab. 11, 453\u2013465. https:\/\/doi.org\/10.1016\/j.cmet.2010.05.001 (2010).","journal-title":"Cell Metab."},{"key":"71491_CR19","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1186\/1476-4598-10-70","volume":"10","author":"M Isra\u00ebl","year":"2011","unstructured":"Isra\u00ebl, M. & Schwartz, L. The metabolic advantage of tumour cells. Mol. Cancer 10, 70. https:\/\/doi.org\/10.1186\/1476-4598-10-70 (2011).","journal-title":"Mol. Cancer"},{"key":"71491_CR20","doi-asserted-by":"publisher","first-page":"837","DOI":"10.7150\/jca.35011","volume":"11","author":"R Liang","year":"2020","unstructured":"Liang, R. et al. STAT3 signalling in ovarian cancer: a potential therapeutic target. J. Cancer 11, 837\u2013848. https:\/\/doi.org\/10.7150\/jca.35011 (2020).","journal-title":"J. Cancer"},{"key":"71491_CR21","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1242\/jcs.209890","volume":"131","author":"EC Arakel","year":"2018","unstructured":"Arakel, E. C. & Schwappach, B. Formation of COPI-coated vesicles at a glance. J Cell Sci 131, 1. https:\/\/doi.org\/10.1242\/jcs.209890 (2018).","journal-title":"J Cell Sci"},{"key":"71491_CR22","doi-asserted-by":"publisher","DOI":"10.1016\/j.drudis.2020.02.007","author":"S Panda","year":"2020","unstructured":"Panda, S., Banerjee, N. & Chatterjee, S. Solute carrier proteins and c-Myc: a strong connection in cancer progression. Drug Discov. Today https:\/\/doi.org\/10.1016\/j.drudis.2020.02.007 (2020).","journal-title":"Drug Discov. Today"},{"key":"71491_CR23","doi-asserted-by":"publisher","first-page":"1318","DOI":"10.1111\/tra.12331","volume":"16","author":"DP Nickerson","year":"2015","unstructured":"Nickerson, D. P. & Merz, A. J. LUCID: A quantitative assay of ESCRT-mediated cargo sorting into multivesicular bodies. Traffic 16, 1318\u20131329. https:\/\/doi.org\/10.1111\/tra.12331 (2015).","journal-title":"Traffic"},{"key":"71491_CR24","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1016\/j.semcdb.2017.05.006","volume":"68","author":"S Sakuma","year":"2017","unstructured":"Sakuma, S. & D\u2019Angelo, M. A. The roles of the nuclear pore complex in cellular dysfunction, aging and disease. Semin. Cell Dev. Biol. 68, 72\u201384. https:\/\/doi.org\/10.1016\/j.semcdb.2017.05.006 (2017).","journal-title":"Semin. Cell Dev. Biol."},{"key":"71491_CR25","doi-asserted-by":"publisher","first-page":"R131","DOI":"10.1186\/bcr3077","volume":"13","author":"T Puig","year":"2011","unstructured":"Puig, T. et al. A novel inhibitor of fatty acid synthase shows activity against HER2+ breast cancer xenografts and is active in anti-HER2 drug-resistant cell lines. Breast Cancer Res. 13, R131. https:\/\/doi.org\/10.1186\/bcr3077 (2011).","journal-title":"Breast Cancer Res."},{"key":"71491_CR26","doi-asserted-by":"publisher","first-page":"8117","DOI":"10.1158\/0008-5472.CAN-09-3871","volume":"70","author":"E Rysman","year":"2010","unstructured":"Rysman, E. et al. De novo lipogenesis protects cancer cells from free radicals and chemotherapeutics by promoting membrane lipid saturation. Cancer Res. 70, 8117\u20138126. https:\/\/doi.org\/10.1158\/0008-5472.CAN-09-3871 (2010).","journal-title":"Cancer Res."},{"key":"71491_CR27","doi-asserted-by":"publisher","first-page":"e72162","DOI":"10.1371\/journal.pone.0072162","volume":"8","author":"MS Anglesio","year":"2013","unstructured":"Anglesio, M. S. et al. Type-specific cell line models for type-specific ovarian cancer research. PLoS ONE 8, e72162. https:\/\/doi.org\/10.1371\/journal.pone.0072162 (2013).","journal-title":"PLoS ONE"},{"key":"71491_CR28","doi-asserted-by":"publisher","first-page":"2126","DOI":"10.1038\/ncomms3126","volume":"4","author":"S Domcke","year":"2013","unstructured":"Domcke, S., Sinha, R., Levine, D. A., Sander, C. & Schultz, N. Evaluating cell lines as tumour models by comparison of genomic profiles. Nat. Commun. 4, 2126. https:\/\/doi.org\/10.1038\/ncomms3126 (2013).","journal-title":"Nat. Commun."},{"key":"71491_CR29","doi-asserted-by":"publisher","first-page":"728","DOI":"10.1002\/msb.20134892","volume":"10","author":"L Yang","year":"2014","unstructured":"Yang, L. et al. Metabolic shifts toward glutamine regulate tumour growth, invasion and bioenergetics in ovarian cancer. Mol. Syst. Biol. 10, 728. https:\/\/doi.org\/10.1002\/msb.20134892 (2014).","journal-title":"Mol. Syst. Biol."},{"key":"71491_CR30","doi-asserted-by":"publisher","first-page":"20989","DOI":"10.1074\/jbc.M117.812925","volume":"292","author":"Y Ma","year":"2017","unstructured":"Ma, Y. et al. The lignan manassantin is a potent and specific inhibitor of mitochondrial complex I and bioenergetic activity in mammals. J. Biol. Chem. 292, 20989\u201320997. https:\/\/doi.org\/10.1074\/jbc.M117.812925 (2017).","journal-title":"J. Biol. Chem."},{"key":"71491_CR31","doi-asserted-by":"publisher","first-page":"970","DOI":"10.1111\/bph.13422","volume":"173","author":"B Bhattacharya","year":"2016","unstructured":"Bhattacharya, B., Mohd Omar, M. F. & Soong, R. The Warburg effect and drug resistance. Br. J. Pharmacol. 173, 970\u2013979. https:\/\/doi.org\/10.1111\/bph.13422 (2016).","journal-title":"Br. J. Pharmacol."},{"key":"71491_CR32","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1242\/jcs.103.2.501","volume":"103","author":"TW Grunt","year":"1992","unstructured":"Grunt, T. W., Somay, C., Oeller, H., Dittrich, E. & Dittrich, C. Comparative analysis of the effects of dimethyl sulfoxide and retinoic acid on the antigenic pattern of human ovarian adenocarcinoma cells. J. Cell Sci. 103, 501\u2013509 (1992).","journal-title":"J. Cell Sci."},{"key":"71491_CR33","doi-asserted-by":"publisher","first-page":"7608","DOI":"10.1158\/1078-0432.CCR-09-0856","volume":"15","author":"T Puig","year":"2009","unstructured":"Puig, T. et al. Novel inhibitors of fatty acid synthase with anticancer activity. Clin. Cancer Res. 15, 7608\u20137615 (2009).","journal-title":"Clin. Cancer Res."},{"key":"71491_CR34","doi-asserted-by":"publisher","first-page":"5013","DOI":"10.1021\/jm2016045","volume":"55","author":"C Turrado","year":"2012","unstructured":"Turrado, C. et al. New synthetic inhibitors of fatty acid synthase with anticancer activity. J. Med. Chem. 55, 5013\u20135023 (2012).","journal-title":"J. Med. Chem."},{"key":"71491_CR35","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1007\/s10549-010-1232-1","volume":"129","author":"C Br\u00fcnner-Kubath","year":"2011","unstructured":"Br\u00fcnner-Kubath, C. et al. The PI3 kinase\/mTOR blocker NVP-BEZ235 overrides resistance against irreversible ErbB inhibitors in breast cancer cells. Breast Cancer Res. Treat 129, 387\u2013400. https:\/\/doi.org\/10.1007\/s10549-010-1232-1 (2011).","journal-title":"Breast Cancer Res. Treat"},{"key":"71491_CR36","doi-asserted-by":"publisher","first-page":"1945","DOI":"10.1021\/acs.analchem.6b04433","volume":"89","author":"A Tahir","year":"2017","unstructured":"Tahir, A. et al. Combined proteome and eicosanoid profiling approach for revealing implications of human fibroblasts in chronic inflammation. Anal. Chem. 89, 1945\u20131954 (2017).","journal-title":"Anal. Chem."},{"key":"71491_CR37","doi-asserted-by":"publisher","first-page":"5502","DOI":"10.1021\/ac100280p","volume":"82","author":"G St\u00fcbiger","year":"2010","unstructured":"St\u00fcbiger, G. et al. Analysis of oxidized phospholipids by MALDI mass spectrometry using 6-aza-2-thiothymine together with matrix additives and disposable target surfaces. Anal. Chem. 82, 5502\u20135510. https:\/\/doi.org\/10.1021\/ac100280p (2010).","journal-title":"Anal. Chem."},{"key":"71491_CR38","doi-asserted-by":"publisher","first-page":"7576","DOI":"10.1021\/ac801200w","volume":"80","author":"G Sun","year":"2008","unstructured":"Sun, G. et al. Matrix-assisted laser desorption\/ionization time-of-flight mass spectrometric analysis of cellular glycerophospholipids enabled by multiplexed solvent dependent analyte-matrix interactions. Anal. Chem 80, 7576\u20137585. https:\/\/doi.org\/10.1021\/ac801200w (2008).","journal-title":"Anal. Chem"},{"key":"71491_CR39","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1016\/j.jprot.2012.07.012","volume":"76","author":"VJ Haudek-Prinz","year":"2012","unstructured":"Haudek-Prinz, V. J. et al. Proteome signatures of inflammatory activated primary human peripheral blood mononuclear cells. J. Proteomics 76, 150\u2013162 (2012).","journal-title":"J. Proteomics"},{"key":"71491_CR40","doi-asserted-by":"publisher","first-page":"5989","DOI":"10.1021\/pr5008625","volume":"13","author":"A Bileck","year":"2014","unstructured":"Bileck, A., Kreutz, D., Muqaku, B., Slany, A. & Gerner, C. Comprehensive assessment of proteins regulated by dexamethasone reveals novel effects in primary human peripheral blood mononuclear cells. J. Proteome Res 13, 5989\u20136000. https:\/\/doi.org\/10.1021\/pr5008625 (2014).","journal-title":"J. Proteome Res"},{"key":"71491_CR41","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1038\/nmeth.1322","volume":"6","author":"JR Wisniewski","year":"2009","unstructured":"Wisniewski, J. R., Zougman, A., Nagaraj, N. & Mann, M. Universal sample preparation method for proteome analysis. Nat. Methods 6, 359\u2013362 (2009).","journal-title":"Nat. Methods"},{"key":"71491_CR42","doi-asserted-by":"publisher","first-page":"1367","DOI":"10.1038\/nbt.1511","volume":"26","author":"J Cox","year":"2008","unstructured":"Cox, J. & Mann, M. MaxQuant enables high peptide identification rates, individualized ppb-range mass accuracies and proteome-wide protein quantification. Nat. Biotechnol 26, 1367\u20131372 (2008).","journal-title":"Nat. Biotechnol"},{"issue":"Suppl 16","key":"71491_CR43","doi-asserted-by":"publisher","first-page":"S12","DOI":"10.1186\/1471-2105-13-S16-S12","volume":"13","author":"J Cox","year":"2012","unstructured":"Cox, J. & Mann, M. 1d and 2d annotation enrichment: a statistical method integrating quantitative proteomics with complementary high-throughput data. BMC Bioinf. 13(Suppl 16), S12. https:\/\/doi.org\/10.1186\/1471-2105-13-S16-S12 (2012).","journal-title":"BMC Bioinf."},{"key":"71491_CR44","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1038\/nprot.2008.211","volume":"4","author":"DW Huang","year":"2009","unstructured":"Huang, D. W., Sherman, B. T. & Lempicki, R. A. Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources. Nat. Protoc. 4, 44\u201357. https:\/\/doi.org\/10.1038\/nprot.2008.211 (2009).","journal-title":"Nat. Protoc."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-020-71491-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-020-71491-z","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-020-71491-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,6]],"date-time":"2022-12-06T18:25:26Z","timestamp":1670351126000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-020-71491-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,9,10]]},"references-count":44,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2020,12]]}},"alternative-id":["71491"],"URL":"https:\/\/doi.org\/10.1038\/s41598-020-71491-z","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,9,10]]},"assertion":[{"value":"13 January 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 July 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 September 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"14877"}}